Sirolimus half-life: how long it stays in your system

Last updated 2026-07-27

What is sirolimus's half-life, exactly?

The FDA label for sirolimus (brand name Rapamune) reports a mean terminal elimination half-life of about 62 hours in stable renal transplant patients taking maintenance doses ^[1]. That number comes from population pharmacokinetic studies in adult transplant recipients, and it's the figure the label itself uses to justify once-daily dosing. Half-life is the time it takes for the concentration of a drug in your blood to drop by half. A 62-hour half-life means that after about 2.6 days, half the drug is gone. After two half-lives (roughly 5 days), a quarter remains. After five half-lives, about 13 days, less than 5% of the original dose is still circulating, which is the standard rule of thumb pharmacologists use to call a drug "cleared." Sirolimus and rapamycin are the same molecule. Rapamycin is the original name, isolated from Streptomyces hygroscopicus soil bacteria found on Easter Island (Rapa Nui) in the 1970s ^[2]. Sirolimus is the generic drug name once it became a marketed pharmaceutical. Whatever it's called, the pharmacokinetics are identical because it's the identical compound. That long half-life is unusual. Most oral drugs clear in hours, not days. It's part of why sirolimus behaves so differently from, say, a daily blood pressure pill, and it's central to how longevity researchers think about intermittent or weekly dosing protocols that have no FDA-reviewed data behind them at all.

How long does sirolimus stay in your system?

Using the 62-hour half-life and the five-half-life clearance rule, sirolimus is largely out of your bloodstream in about 13 to 14 days after the last dose ^[1]. That's the number people usually mean when they ask how long it "stays in your system." But clearance isn't all-or-nothing. Trace amounts can be detectable longer than that, especially with sensitive lab assays, and individual half-life varies a fair amount. Studies in transplant patients have found the terminal half-life ranging anywhere from about 46 hours to well over 100 hours depending on the patient population, liver function, and co-administered drugs ^[3]. For someone on a weekly off-label dosing protocol (a single larger dose once a week, which is the pattern most longevity users and prescribers discuss, modeled loosely on intermittent-dosing mouse studies), that 62-hour half-life means blood levels are dropping for most of the week between doses, but a full week is more than two and a half half-lives, so levels don't reach zero before the next dose. There is no FDA-approved or clinically validated weekly protocol; anyone taking it this way needs actual trough level monitoring, not a half-life estimate, because individual variation is large. See our Sirolimus Rx dosage and Sirolimus Rx cycle length pages for how these intervals are typically structured.

How long until sirolimus reaches steady-state blood levels?

With daily dosing, it takes about 6 days to reach steady-state concentration, since steady-state is generally reached after roughly four to five half-lives of consistent dosing, and 4 to 5 times 62 hours lands right around 5 to 6 days ^[1]. This is why transplant protocols typically use a loading dose on day one, to get blood levels up faster instead of waiting a week for them to climb on their own. Steady-state matters because a single blood level, drawn at a random time, tells you very little. Trough levels (drawn right before the next dose, at the lowest point in the cycle) are the only levels that are clinically standardized and interpretable, and even those aren't meaningful until steady-state is reached, generally after about a week of consistent dosing ^[1]. For weekly or twice-weekly off-label regimens, there isn't a validated steady-state concept in the same way, because the whole point of intermittent dosing (based on the mouse ITP protocols, discussed below) is to spike blood levels high and then let them fall, not to hold a flat concentration. That's a meaningfully different pharmacokinetic goal than transplant dosing, and it's one reason data from transplant patients doesn't translate cleanly to longevity protocols.

Why does sirolimus have such a long half-life compared to other drugs?

Sirolimus is highly lipophilic (fat-soluble) and binds extensively to red blood cells and tissue, which slows its release back into circulation ^[1]. It's also metabolized primarily by the liver enzyme CYP3A4 and moved around by P-glycoprotein transporters, both of which are slow, saturable systems compared to, say, renal filtration of a water-soluble drug ^[1]. This is the same general family of behavior seen in other CYP3A4-metabolized, highly protein-bound drugs, but sirolimus's half-life is genuinely long even within that group. Compare it to tacrolimus, another transplant immunosuppressant, which has a half-life of roughly 12 hours in adults, about a fifth of sirolimus's, per its FDA labeling ^[4]. That's why tacrolimus needs twice-daily dosing and sirolimus doesn't. Food and liver function change absorption and clearance meaningfully. The FDA label notes that a high-fat meal increases peak sirolimus concentration and delays time to peak, which is part of why consistency (taking it the same way relative to food, every time) matters more than which specific way you choose ^[1].

Does the half-life change with liver problems, age, or drug interactions?

Yes. Sirolimus clearance depends heavily on liver function and on interactions with CYP3A4/P-glycoprotein, and the label specifically calls out reduced-dose recommendations for hepatic impairment ^[1]. Strong CYP3A4 inhibitors (ketoconazole, certain macrolide antibiotics, some antifungals, grapefruit juice) slow sirolimus metabolism and can raise blood levels substantially, effectively extending the practical half-life and increasing exposure. Strong CYP3A4 inducers (rifampin, certain anticonvulsants, St. John's Wort) do the opposite, lowering levels ^[1]. This is why the FDA label carries specific dosing adjustment guidance around these interacting drugs rather than a single fixed number for everyone. Age doesn't change the half-life dramatically in adults per the label's pharmacokinetic data, but hepatic impairment does, and the label recommends roughly a one-third dose reduction in patients with mild to moderate hepatic impairment, with closer monitoring in severe impairment ^[1]. Anyone with liver disease considering off-label sirolimus for any reason should treat this as a hard stop for a conversation with a prescriber, not a footnote.

What does the half-life mean for dosing frequency (daily vs weekly)?

The FDA-approved dosing schedule for sirolimus is once daily, which fits its roughly 62-hour half-life reasonably well for maintaining steady immunosuppression in transplant patients ^[1]. Once-daily dosing at steady state keeps troughs and peaks within a fairly narrow, predictable range, which is exactly what you want when the goal is continuous, stable immune suppression to prevent organ rejection. Off-label longevity protocols instead often use once-weekly or twice-weekly dosing, an approach borrowed conceptually from the mouse studies run by the National Institute on Aging's Interventions Testing Program (ITP), which dosed rapamycin intermittently in chow and found lifespan extension in genetically heterogeneous mice ^[5]. The logic some researchers give for intermittent human dosing is to hit mTORC1 hard periodically while letting levels fall between doses, in theory sparing mTORC2 and reducing side effects like glucose intolerance. This is a hypothesis extrapolated from animal data and small human pharmacokinetic/pharmacodynamic studies, not a proven human protocol. The half-life is the reason weekly-dosing math even seems plausible: a week is a little under 2.75 half-lives, so levels fall substantially, but they don't reset to zero, meaning even weekly dosing has carryover between doses. Anyone adjusting frequency without blood level monitoring is doing so blind. See Sirolimus Rx dosage calculator for how clinicians typically frame these intervals against body weight and target levels.

How is the half-life relevant to the longevity and anti-aging claims?

The half-life itself doesn't prove or disprove anything about aging, but it's the pharmacokinetic backbone for every longevity dosing protocol being discussed today, and it's worth separating the pharmacology (solid, well-characterized) from the aging claims (unproven in humans). The animal evidence is genuinely strong. The NIA's Interventions Testing Program has repeatedly found that rapamycin extends median and maximum lifespan in mice, including a 2009 study in Nature showing extended lifespan even when dosing started late in life, at 600 days of age (roughly equivalent to a 60-year-old human) ^[5]. Later ITP cohorts confirmed the effect at multiple doses and found it worked in both sexes, though female mice sometimes showed larger relative gains ^[6]. There is, as of this writing, no completed human randomized controlled trial demonstrating that sirolimus or rapamycin extends human lifespan or healthspan. This is the single most important thing to understand about the entire subject: the mouse data is some of the most replicated in aging biology, and the human outcome data does not exist yet. Small human studies have looked at surrogate markers, immune function in the elderly, and short-term biomarkers, but nothing has looked at actual human lifespan extension with a completed trial. Anyone telling you sirolimus is "proven" to extend human life is overstating the evidence regardless of how good the mouse data is.

What are the real risks tied to sirolimus's pharmacokinetics: immunosuppression, mouth ulcers, metabolic effects?

Because sirolimus's mechanism (mTOR inhibition) is the same regardless of dose or schedule, the core side effects show up in both FDA-approved transplant use and off-label longevity use, just at different frequencies and severity depending on dose and interval. Immunosuppression is the headline risk, since sirolimus is FDA-approved specifically as an immunosuppressant to prevent organ transplant rejection ^[1]. At transplant doses, this means real, clinically significant increased infection risk, which is the whole point of the drug in that context. At the much lower, intermittent doses used off-label for longevity, the immunosuppressive effect is presumed to be smaller, but there is no large human safety dataset confirming what infection risk looks like at these doses over years of use. Mouth ulcers (stomatitis) are one of the most commonly reported side effects even at lower off-label doses, showing up in a meaningful share of users based on both the FDA label's adverse event data from transplant trials and anecdotal reports from longevity users ^[1]. They tend to be dose-related and often improve with dose reduction or timing changes. Metabolic effects are also well documented in the label: sirolimus is associated with elevated triglycerides, elevated cholesterol, and in some patients, new-onset or worsened glucose intolerance and insulin resistance ^[1]. This is mechanistically tied to mTOR inhibition itself, and it's part of why some researchers favor intermittent dosing (theorizing it may spare mTORC2, which is more involved in insulin signaling) over daily dosing, though this remains a hypothesis, not an established clinical fact in humans. Other labeled risks include impaired wound healing, elevated blood pressure, and rare but serious lung toxicity (interstitial lung disease) ^[1]. None of these are hypothetical; they're documented adverse effects from the drug's approved use, and off-label users take on unknown versions of the same risk profile without the structured monitoring a transplant patient gets.

How does the half-life affect drug testing, surgery, and stopping treatment?

If you need to stop sirolimus before surgery or a procedure, the roughly 62-hour half-life means it takes about 2 weeks for the drug to clear substantially from your system, which is the window most surgical guidance and transplant center protocols use when discussing perioperative immunosuppressant management, since sirolimus is separately flagged for wound healing complications ^[1]. For anyone monitoring blood levels (which is standard for transplant dosing and strongly recommended for any off-label longevity use), trough levels only become meaningful after steady-state is reached, about a week of consistent dosing, and levels won't reflect a dose change accurately until another week has passed ^[1]. This is why prescribers don't chase single blood draws; they wait for the pharmacokinetics to settle. If you're switching from one dosing schedule to another (daily to weekly, or adjusting a weekly dose), expect roughly one to two weeks before blood levels reflect the new steady pattern. This is also why home-use dosing without periodic labs is a real gap in most off-label longevity regimens: the half-life is long enough that mistakes (wrong dose, missed dose, drug interaction) don't show up quickly, and by the time a level is checked, weeks of miscalibrated exposure may have already happened.

How should this pharmacokinetic profile shape a practical dosing decision?

The half-life data supports a few concrete, defensible practices regardless of where you land on the aging-hype question. First, consistency in timing relative to food matters, since a high-fat meal changes peak concentration and absorption timing ^[1]. Second, dose changes need at least a week, ideally two, before you judge their effect on blood levels, because that's how long it takes to reach a new steady state. Third, anyone on interacting medications (macrolide antibiotics, azole antifungals, certain anticonvulsants) needs specific guidance from a prescriber, because these can shift effective exposure substantially without changing the dose at all ^[1]. If you're evaluating a provider-reviewed off-label protocol, look for one that includes baseline labs, periodic blood level or safety monitoring, and a real prescriber relationship rather than a fixed shipped protocol with no oversight. Sirolimus Rx connects patients with licensed prescribers who review history and order appropriate monitoring, with prescriptions filled through a licensed U.S. pharmacy partner, which is the structure that actually accounts for the pharmacokinetic realities described above rather than ignoring them. See Sirolimus Rx dosage, how to reconstitute Sirolimus Rx, Sirolimus Rx how to inject, and Sirolimus Rx injection sites for the practical side of following a protocol correctly once you and a prescriber have settled on one.

Frequently asked questions

What is the half-life of sirolimus (rapamycin)?

The FDA label reports a mean terminal elimination half-life of about 62 hours in stable adult transplant patients on maintenance dosing. Individual half-life varies with liver function and interacting drugs, with reported ranges from roughly 46 to over 100 hours in different patient populations.

How long does it take for sirolimus to fully leave your body?

Using the standard five-half-life clearance estimate and a 62-hour half-life, sirolimus is largely cleared from the bloodstream in about 13 to 14 days after the last dose. Trace amounts may be detectable slightly longer with sensitive lab assays.

Is sirolimus the same as rapamycin?

Yes. Rapamycin is the original compound name, isolated from Streptomyces hygroscopicus bacteria found on Easter Island in the 1970s. Sirolimus is the generic pharmaceutical name for the identical molecule once it was developed and approved as a drug.

Why is sirolimus dosed once a day instead of multiple times daily?

Its roughly 62-hour half-life is long enough that once-daily dosing maintains fairly stable blood concentrations at steady state, unlike shorter-half-life drugs (tacrolimus, at about 12 hours, needs twice-daily dosing). The FDA-approved schedule reflects this pharmacokinetic profile.

How long does it take for sirolimus blood levels to stabilize (reach steady state)?

About 6 days of consistent daily dosing, based on the rule that steady-state takes roughly 4 to 5 half-lives and sirolimus's half-life is about 62 hours. This is why transplant protocols often use a loading dose to raise levels faster instead of waiting.

Does sirolimus's half-life change with weekly off-label dosing protocols?

The molecule's half-life doesn't change, but weekly dosing creates a different exposure pattern: levels fall for most of the week but don't reach zero before the next dose, since a week is under three half-lives. No FDA-reviewed data validates a specific weekly protocol; individual monitoring matters.

Does liver disease affect how long sirolimus stays in your system?

Yes. The FDA label recommends roughly a one-third dose reduction in patients with mild to moderate hepatic impairment because sirolimus is metabolized primarily by the liver, and impaired liver function slows clearance and raises effective exposure.

Does rapamycin actually extend human lifespan?

There is no completed human trial proving this. The evidence is strong in mice, notably the NIA Interventions Testing Program, which found lifespan extension even starting treatment at 600 days of age. Human data is limited to small studies on biomarkers and immune function, not lifespan outcomes.

What are the biggest risks of taking sirolimus off-label for longevity?

Immunosuppression (increased infection risk, since it's FDA-approved as an immunosuppressant), mouth ulcers (a commonly reported side effect even at lower doses), and metabolic effects including elevated triglycerides, cholesterol, and glucose intolerance are all documented risks tied to its mechanism, more than its approved use.

How long before surgery should sirolimus be stopped?

Because full clearance takes roughly two weeks given the 62-hour half-life, and sirolimus is separately linked to impaired wound healing, many surgical and transplant protocols plan around a similar window. This should always be confirmed with the prescribing provider and surgical team, not estimated independently.

Why do some longevity researchers prefer intermittent dosing over daily dosing?

The theory, drawn from the mouse ITP protocols and some human pharmacodynamic studies, is that intermittent high-dose exposure may hit mTORC1 while sparing mTORC2 (more involved in insulin signaling and metabolic side effects), between doses. This remains a hypothesis in humans, not an established clinical outcome.

How does sirolimus's half-life compare to other transplant immunosuppressants?

Sirolimus's roughly 62-hour half-life is much longer than tacrolimus's roughly 12-hour half-life, which is why sirolimus supports once-daily or less-frequent dosing while tacrolimus requires twice-daily dosing to maintain stable levels.

Sources

1. FDA, Rapamune (sirolimus) prescribing information, label revision 2015 (NDA 021083): Mean terminal elimination half-life of about 62 hours, dosing, food effect, hepatic impairment adjustment, and adverse effect profile
2. NIH National Library of Medicine, StatPearls: Sirolimus: Rapamycin origin from Streptomyces hygroscopicus and mechanism of mTOR inhibition
3. National Library of Medicine, PubMed pharmacokinetics review of sirolimus: Reported half-life variability across transplant patient populations
4. FDA, Prograf (tacrolimus) prescribing information, drug approval package (NDA 050708): Tacrolimus half-life of approximately 12 hours, contrasted with sirolimus
5. Harrison et al., "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice," Nature (2009), PMID 19587680: Rapamycin extended lifespan in mice even when treatment started at 600 days of age
6. Miller et al., "Rapamycin-mediated lifespan increase in mice is dose and sex dependent...", Aging Cell (2014), PMID 24245565: NIA ITP repeated and confirmed rapamycin lifespan extension findings across cohorts and doses, with sex differences in magnitude